First-in-man clinical study of SCMod1 [Modi-1] for cancer

Trial Profile

First-in-man clinical study of SCMod1 [Modi-1] for cancer

Planning
Phase of Trial: Phase I/II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs SCMod1 (Primary)
  • Indications Breast cancer; Endometrial cancer; Osteosarcoma; Ovarian cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 13 Sep 2017 According to a Scancell media release, the company is aiming to file a Clinical Trial Application (CTA) in the UK for the planned Phase 1/2 clinical trial in breast cancer, ovarian cancer and sarcoma in 2018.
    • 16 Sep 2016 According to Scancell media release, enrolment for triple negative breast cancer, ovarian cancer and osteosarcoma expected to commence in early 2018.
    • 27 Jan 2016 According to a Scancell media release, clinical studies are scheduled to start in 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top